Pfizer is stopping development of its experimental oral GLP-1 drug for obesity after a patient in a trial suffered a liver injury potentially caused by the drug. The patient did not experience any symptoms, and the injury resolved after discontinuation of the drug, Pfizer said. After reviewing all clinical data for the medicine and consulting with regulators, Pfizer said it decided to halt research on it. The case occurred in a dose optimization trial, aimed at finding the highest tolerable dose in a short amount of time.
